Зебраданио (zebrafish) как модель редких (орфанных) заболеваний нервной системы

   Редкие (орфанные) заболевания – биомедицинская проблема мирового уровня. На поиск лекарств от этих заболеваний затрачиваются огромные усилия и средства. Зебраданио (zebrafish) могут обеспечить скрининг новых лекарственных препаратов, углубить понимание редких патологических состояний. В этом обзоре рассмотрены различные модели орфанных заболеваний нервной системы на зебраданио и связанные с ними проблемы и перспективы в контексте развития персонализированной медицины.

1. Food and Drug Administration (FDA). Public Law 97-414. Orphan Drug Act. 1983; 2049–2066.

2. Orphanet. https://www.orpha.net/consor/cgi-bin/index.php.

3. Brewer G. J. Drug development for orphan diseases in the context of personalized medicine. Transl. Res. 2009; 154: 314–32.

4. Joppi R., Bertele’ V., Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur. J. Clin. Pharmacol. 2013; 69: 1009–1024.

5. Федеральный закон № 323-ФЗ от 21 ноября 2011 года «Об основах охраны здоровья граждан в Российской Федерации». Ст. 44.

6. Перечень редких (орфанных) заболеваний. https://minzdrav.gov.ru/documents/9641-perechen-redkih-orfannyh-zabolevaniy.

7. Распространенность психических расстройств (%) — Европейский портал информации здравоохранения. https://gateway.euro.who.int/ru/indicators/hfa_391-2410-prevalence-of-mental-disorders/visualizations/#id=19322&tab=table.

8. Genetic and Rare Diseases Information Center (GARD) — an NCATS Program | Providing information about rare or genetic diseases. https://rarediseases.info.nih.gov/.

9. Behavioral and mental disorders | Genetic and Rare Diseases Information Center (GARD) — an NCATS Program. https://rarediseases.info.nih.gov/diseases/diseases-by-category/3/behavioral-and-mental-disorders.

10. Bergink V. The prevalence of rare diseases in psychiatry. The Lancet Psychiatry 2018;5:693–694.

11. Barbazuk W. B., et al. The syntenic relationship of the zebrafish and human genomes. Genome Res. 2000; 10: 1351–1358.

12. Dahlbom S. J., Backström T., Lundstedt-Enkel K., Winberg S. Aggression and monoamines: Effects of sex and social rank in zebrafish (Danio rerio). Behav. Brain Res. 2012; 228: 333–338.

13. Fontana B. D., Mezzomo N. J., Kalueff A. V., Rosemberg D. B. The developing utility of zebrafish models of neurological and neuropsychiatric disorders: A critical review. Exp. Neurol. 2018; 299: 157–171.

14. Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Curr. Opin. Pharmacol. 2004; 4: 504–512.

15. Галстян Д. С. Острые поведенческие эффекты целебрекса у взрослых зебраданио / Д. С. Галстян [и др.] // Фундаментальная наука и клиническая медицина. – 2021; 24: 818–819.

16. Burton D. F., et al. Pharmacological activation of the Sonic hedgehog pathway with a Smoothened small molecule agonist ameliorates the severity of alcohol-induced morphological and behavioral birth defects in a zebrafish model of fetal alcohol spectrum disorder. J. Neurosci. Res. 2022. DOI: 10.1002/JNR.25008.

17. Klee E. W., Ebbert J. O., Schneider H., Hurt R. D., Ekker S. C. Zebrafish for the Study of the Biological Effects of Nicotine. Nicotine Tob. Res. 2011; 13, 301–312.

18. Zon L. I., Peterson R. T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 2005; 41 4: 35–44.

19. Dinday M. T., Baraban S. C. Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome. eNeuro. 2, 2015.

20. de Abreu M. S., et al. Emotional behavior in aquatic organisms? Lessons from crayfish and zebrafish. J. Neurosci. Res. 2020; 98: 764–779.

21. Prabhudesai S., et al. LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. J. Neurosci. Res.2016; 94: 717–735.

22. Мешалкина Д. А. Получение линий зебраданио, нокаутных по генам транспортеров серотонина (slc6a4a и slc6a4b) с помощью направленного редактирования системами CRISPR/SpCas9 и CRISPR/LbCas12a / Д. А. Мешалкина [и др.] // VII Съезд Вавиловского общества генетиков и селекционеров, посвященный 100-летию кафедры генетики СПбГУ, и ассоциированные симпозиумы : Cборник тезисов Международного конгресса. – 2019: 753.

23. Fonseka T. M., Wen X. Y., Foster J. A., Kennedy S. H. Zebrafish models of major depressive disorders. J. Neurosci. Res. 2016; 94: 3–14.

24. de Abreu M. S., et al. Zebrafish models: do we have valid paradigms for depression? J. Pharmacol. Toxicol. Methods. 2018; 94: 16–22.

25. Campbell P. D., Granato M. Zebrafish as a tool to study schizophrenia-associated copy number variants. DMM Dis. Model. Mech. 13, 2020.

26. Demin K. A., et al. Developing zebrafish experimental animal models relevant to schizophrenia. Neurosci. Biobehav. Rev. 2019; 105: 126–133.

27. Gawel K., Banono N. S., Michalak A., Esguerra C. V. A critical review of zebrafish schizophrenia models: Time for validation? Neurosci. Biobehav. Rev. 2019; 107: 6–22.

28. Sager J. J., Bai Q., Burton E. A. Transgenic zebrafish models of neurodegenerative diseases. DOI: 10.1007/s00429-009-0237-1.

29. McColgan P., Tabrizi S. J. Huntington’s disease: a clinical review. Eur. J. Neurol. 2018; 25: 24–34.

30. Walker F. O. Huntington’s disease. Lancet. 2007; 369: 218–228.

31. Karlovich C. A., John R. M., Ramirez L., Stainier D. Y. R., Myers R. M. Characterization of the Huntington’s disease (HD) gene homolog in the zebrafish Danio rerio. Gene. 1998; 217: 117–125.

32. Lumsden A. L., Henshall T. L., Dayan S., Lardelli M. T., Richards R. I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. Mol. Genet. 2007; 16: 1905–1920.

33. Diekmann H., et al. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009; 29: 1343–1349.

34. Henshall T. L., et al. Selective neuronal requirement for huntingtin in the developing zebrafish. Hum. Mol. Genet. 2009; 18: 4830.

35. Schiffer N. W., et al. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J. Biol. Chem. 2007; 282: 9195–9203.

36. Miller V. M., et al. CHIP Suppresses Polyglutamine Aggregation and Toxicity In Vitro and In Vivo. J. Neurosci. 2005; 25: 9152.

37. Williams A., et al. Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 2008; 4: 295–305.

38. Veldman M. B., et al. The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model. Mol. Neurodegener. 10, 2015.

39. Rudnik-Schöneborn S., Barth P. G., Zerres K. Pontocerebellar hypoplasia. Am. J. Med. Genet. Part C Semin. Med. Genet. 2014; 166: 173–183.

40. Kasher P. R., et al. Impairment of the tRNA-splicing endonuclease subunit 54 (tsen54) gene causes neurological abnormalities and larval death in zebrafish models of pontocerebellar hypoplasia. Hum. Mol. Genet. 2011; 20: 1574–1584.

41. Schaffer A. E., et al. CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. Cell. 2014; 157: 651–663.

42. Boczonadi V., et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat. Commun. 2014; 51 5: 1–13.

43. Burns D. T., et al. Variants in EXOSC9 Disrupt the RNA Exosome and Result in Cerebellar Atrophy with Spinal Motor Neuronopathy. Am. J. Hum. Genet. 2018; 102: 858–873.

44. Müller J. S., et al. RNA exosome mutations in pontocerebellar hypoplasia alter ribosome biogenesis and p53 levels. Life Sci. alliance. 3, 2020.

45. Moreno-García A., Kun A., Calero O., Medina M., Calero M. An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Front. Neurosci. 12, 2018.

46. Dragos A. Nita, Sara E. Mole, Minassian B. A. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016; 18: S73–S88.

47. Mahmood F., et al. A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain 2013; 136: 1488–1507.

48. Mahmood F., Zdebik A., Au A., Cooke J., Russell C. Valproic acid extends lifespan of the zebrafish model of CLN2 disease (late infantile neuronal ceroid lipofuscinosis). J. Neurol. Neurosurg. Psychiatry 86, e4.153-e4; 2015.

49. Wager K., et al. Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease). PLoS One. 11, 2016.

50. Rosenbaum A. I., Maxfield F. R. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J. Neurochem. 2011; 116: 789–795.

51. Toledano-Zaragoza A., Ledesma M. D. Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases. Neuropharmacology. 171, 2020.

52. Cook S. R., et al. Visualisation of cholesterol and ganglioside GM1 in zebrafish models of Niemann-Pick type C disease and Smith-Lemli-Opitz syndrome using light sheet microscopy. Histochem. Cell Biol. 2020; 154: 565–578.

53. Lin Y., Cai X., Wang G., Ouyang G., Cao H. Model construction of Niemann-Pick type C disease in zebrafish. Biol. Chem. 2018; 399: 903–910.

54. Louwette S., et al. NPC1 defect results in abnormal platelet formation and function: studies in Niemann-Pick disease type C1 patients and zebrafish. Hum. Mol. Genet. 2013; 22: 61–73.

55. Wiweger M., Majewski L., Adamek-Urbanska D., Wasilewska I., Kuznicki J. npc2-Deficient Zebrafish Reproduce Neurological and Inflammatory Symptoms of Niemann-Pick Type C Disease. Front. Cell. Neurosci. 15, 2021.

56. Schwend T., Loucks E. J., Snyder D., Ahlgren S. C. Requirement of Npc1 and availability of cholesterol for early embryonic cell movements in zebrafish. J. Lipid Res. 2011; 52: 1328.

57. Tseng W. C., et al. Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for in vivo screening of candidate therapeutic compounds. Dis. Model. Mech. 11, 2018.

58. Tseng W. C, et al. The role of Niemann-Pick type C2 in zebrafish embryonic development. Dev. 148, 2021.

59. Thijs R. D., Surges R., O’Brien T. J., Sander J. W. Epilepsy in adults. Lancet. 2019; 393: 689–701.

60. Löscher W. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs. Neurochem. Res. 2017; 42: 1873–1888.

61. Macdonald R. L., Barker J. L. Specific antagonism of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: A common mode of convulsant action. Neurology. 1978; 28: 325–330.

62. Gallitto G., et al. Pentylenetetrazol-induced spike wave discharges in rats: A polygraphic study. Ital. J. Neurol. Sci. 1987; 8: 143–150.

63. Afrikanova T., et al. Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs. PLoS One. 8, 2013.

64. Watanabe Y., Takechi K., Fujiwara A., Kamei C. Effects of antiepileptics on behavioral and electroencephalographic seizure induced by pentetrazol in mice. J. Pharmacol. Sci. 2010; 112: 282–289.

65. Berghmans S., Hunt J., Roach A., Goldsmith P. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Res. 2007; 75: 18–28.

66. Leclercq K., et al. Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish. Epilepsy Behav. 2015; 45: 53–63.

67. Zhang Y., et al. Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish. Sci. Reports. 2017; 71 7: 1–13.

68. Langlois M., et al. Involvement of the thalamic parafascicular nucleus in mesial temporal lobe epilepsy. J. Neurosci. 2010; 30: 16523–16535.

69. Mussulini B. H. M., et al. Forebrain glutamate uptake and behavioral parameters are altered in adult zebrafish after the induction of Status Epilepticus by kainic acid. Neurotoxicology. 2018; 67: 305–312.

70. Wong K., et al. Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish. Brain Res. 2010; 1348: 209–215.

71. Stewart A. M., et al. Perspectives of zebrafish models of epilepsy: What, how and where next? Brain Res. Bull. 2012; 87: 135–143.

72. Lee G. H., et al. Zebrafish larvae exposed to ginkgotoxin exhibit seizure like behavior that is relieved by pyridoxal-5′-phosphate, GABA and anti-epileptic drugs. DMM Dis. Model. Mech. 2012; 5: 785–795.

73. Lopes M. W., Sapio M. R., Leal R. B., Fricker L. D. Knockdown of carboxypeptidase A6 in zebrafish larvae reduces response to seizure-inducing drugs and causes changes in the level of mRNAs encoding signaling molecules. PLoS One. 11, 2016.

74. Novak A. E., et al. Embryonic and larval expression of zebrafish voltage-gated sodium channel ′-subunit genes. Dev. Dyn. 2006; 235: 1962–1973.

75. Baraban S. C., Dinday M. T., Hortopan G. A. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat. Commun. 4, 2013.

76. Cross J. H., et al. Neurological features of epilepsy, ataxia, sensorineural deafness, tubulopathy syndrome. Dev. Med. Child Neurol. 2013; 55: 846–856.

77. Mahmood F., et al. Generation and validation of a zebrafish model of EAST (epilepsy, ataxia, sensorineural deafness and tubulopathy) syndrome. DMM Dis. Model. Mech.2013; 6: 652–660.

78. Zdebik A. A., et al. Epilepsy in kcnj10 morphant zebrafish assessed with a novel method for long-term EEG recordings. PLoS One. 8, 2013.

79. Chege S. W., Hortopan G. A., Dinday M. T., Baraban S. C. Expression and function of KCNQ channels in larval zebrafish. Dev. Neurobiol. 2012; 72: 186–198.

80. Saitsu H., et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat. Genet. 2008; 40: 782–788.

81. Grone B. P., et al. Epilepsy, behavioral abnormalities, and physiological comorbidities in syntaxin-binding protein 1 (STXBP1) mutant zebrafish. PLoS One. 11, 2016.

82. Verhage M., et al. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science (80-. ).2000; 287: 864–869.

83. Gawel K., et al. Seizing the moment: Zebrafish epilepsy models. Neurosci. Biobehav. Rev. 2020; 116: 1–20.

84. Suls A., et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with dravet syndrome. Am. J. Hum. Genet. 2013; 93: 967–975.

85. Ottman R., et al. Localization of a gene for partial epilepsy to chromosome 10q. Nat. Genet. 1995; 10: 56–60.

86. Gu W., et al. Using gene-history and expression analyses to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol. 2005; 22: 2209–2216.

87. Teng Y., et al. Loss of zebrafish lgi1b leads to hydrocephalus and sensitization to pentylenetetrazol induced seizure-like behavior. PLoS One. 6, 2011.

88. Teng Y., et al. Knockdown of zebrafish lgi1a results in abnormal development, brain defects and a seizure-like behavioral phenotype. Hum. Mol. Genet. 2010; 19: 4409–4420.

89. Dibbens L. M., et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat. Genet. 2013; 45: 546–551.

90. de Calbiac H., et al. Depdc5 knockdown causes mTOR-dependent motor hyperactivity in zebrafish. Ann. Clin. Transl. Neurol. 2018; 5: 510–523.

91. Pena I. A., et al. Pyridoxine-dependent epilepsy in zebrafish caused by aldh7a1 deficiency. Genetics 2017; 207: 1501–1518.

92. Johnstone D. L., et al. PLPHP deficiency: Clinical, genetic, biochemical, and mechanistic insights. Brain. 2019; 142: 542–559.

93. Goi L. D. S., Altenhofen S., Nabinger D. D., Bonan C. D., Sato D. K. Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish. J. Neuroimmunol. 359, 2021.

94. Fang Z., et al. Advances in autoimmune epilepsy associated with antibodies, their potential pathogenic molecular mechanisms, and current recommended immunotherapies. Front. Immunol. 2017; 8: 395.

95. Binks S. N. M., Klein C. J., Waters P., Pittock S. J., Irani S. R. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J. Neurol. Neurosurg. Psychiatry. 2018; 89: 526–534.

96. Goody M. F., Sullivan C., Kim C. H. Studying the immune response to human viral infections using zebrafish. Dev. Comp. Immunol. 2014; 46: 84–95.

97. Silva M. T. T. Viral encephalitis. Arq. Neuropsiquiatr. 2013; 71: 703–709.

98. Thapar A., Rutter M. Neurodevelopmental disorders. Rutter’s Child Adolesc. Psychiatry Sixth Ed.2015; 31–40. DOI: 10.1002/9781118381953.CH3.

99. Sakai C., Ijaz S., Hoffman E. J. Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future. Front. Mol. Neurosci. 2018; 11: 294.

100. Connors S. L., et al. Fetal Mechanisms in Neurodevelopmental Disorders. Pediatr. Neurol. 2008; 38: 163–176.

101. Tran N. Q. V., Miyake K. Neurodevelopmental Disorders and Environmental Toxicants: Epigenetics as an Underlying Mechanism. Int. J. Genomics. 2017.

102. Marín O. Interneuron dysfunction in psychiatric disorders. Nat. Rev. Neurosci. 2012; 13: 107–120.

103. Stainier D. Y. R., et al. Guidelines for morpholino use in zebrafish. PLOS Genet. 13, e1007000, 2017.

104. Garber K. B., Visootsak J., Warren S. T. Fragile X syndrome. Eur. J. Hum. Genet. 2008; 166 16: 666–672.

105. Hunter J., et al. Epidemiology of fragile X syndrome: A systematic review and meta-analysis. Am. J. Med. Genet. Part A. 2014; 164: 1648–1658.

106. Hagerman R. J., et al. Fragile X syndrome. Nat. Rev. Dis. Prim. 2017; 31 3: 1–19.

107. van’t Padje S., et al. Characterisation of Fmrp in zebrafish: Evolutionary dynamics of the fmr1 gene. Dev. Genes Evol. 2005; 215: 198–206.

108. Kim L., et al. Anxiety, hyperactivity and stereotypy in a zebrafish model of fragile X syndrome and autism spectrum disorder. Prog. Neuro-Psychopharmacology Biol. Psychiatry. 2014; 55: 40–49.

109. Ng M. C., Yang Y. L., Lu K. T. Behavioral and Synaptic Circuit Features in a Zebrafish Model of Fragile X Syndrome. PLoS One 8, e51456, 2013.

110. Goutières F. Aicardi-Goutières syndrome. Brain Dev. 2005; 27: 201–206.

111. Crow Y. J., et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am. J. Med. Genet. Part A. 2015; 167: 296–312.

112. Kasher P. R., et al. Characterization of samhd1 Morphant Zebrafish Recapitulates Features of the Human Type I Interferonopathy Aicardi-Goutières Syndrome. J. Immunol. 2015; 194: 2819–2825.

113. Rice G. I., et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 2009; 417 41: 829–832.

114. Cortelazzo A., et al. Proteomic analysis of the Rett syndrome experimental model mecp2Q63X mutant zebrafish. J. Proteomics. 2017; 154: 128–133.

115. Chahrour M., Zoghbi H. Y. The Story of Rett Syndrome: From Clinic to Neurobiology. Neuron. 2007; 56: 422–437.

116. Ragione F. Della, Vacca M., Fioriniello S., Pepe G., D’Esposito M. MECP2, a multi-talented modulator of chromatin architecture. Brief. Funct. Genomics. 2016; 15, 420–431.

117. Maunakea A. K., Chepelev I., Cui K., Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 2013; 2311 23: 1256–1269.

118. De Felice C., et al. Subclinical myocardial dysfunction in Rett syndrome. Eur. J. Echocardiogr.2012; 13, 339–345).

119. Howe K., et al. The zebrafish reference genome sequence and its relationship to the human genome. Nat. 2013; 4967446 496: 498–503.

120. Vaz R., Hofmeister W., Lindstrand A. Zebrafish models of neurodevelopmental disorders: Limitations and benefits of current tools and techniques. Int. J. Mol. Sci. 20, 2019.

121. Li D., et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat. Med. 2019; 257 25: 1116–1122.

122. Usai A., et al. A Model of a Zebrafish Avatar for Co-Clinical Trials. Cancers 2020, Vol. 12, P. 677.

123. Costa B., Estrada M. F., Mendes R. V., Fior R. Zebrafish Avatars towards Personalized Medicine-A Comparative Review between Avatar Models. Cells 9, 2020.

124. Williams C. H., Hong C. C. Zebrafish small molecule screens: Taking the phenotypic plunge. Comput. Struct. Biotechnol. J. 2016; 14: 350–356.